GET DAILY SIGNALSWhy Is Haleon (HLN) Stock Down -12.6% Today?
Key Takeaways
- Shares of HLN plunged 12.6% to $8.74, down from a prior session close of $10.00.
- Primary catalyst: The company cut its full-year 2026 organic revenue growth guidance to about 2.5%, down from a prior range of 3% to 5%.
- Secondary drivers: Weak cough, cold, and flu demand in North America, a regulatory setback on Centrum imports in China, and an accelerated restructuring in Brazil.
- Bright spots: Oral Health revenue rose 8.8% organically, and the company announced an additional £500 million share buyback.
- Broader context: Consumer-health peers remain under pressure, with rival Reckitt also trimming guidance earlier in the week.
- What's next: Traders are watching for a cold-and-flu season recovery, a resolution of the China import issue, and execution of the Brazil transition.
- For more detail on valuation levels, see Price Targets, review upcoming Earnings dates, and check the latest Forecast.
- Explore Trending AI Robots to see which AI-driven trading strategies are performing best under current market conditions.
Opening Summary
Haleon plc (HLN), the British consumer healthcare group behind brands such as Sensodyne, Panadol, Advil, Centrum, and Voltaren, suffered a sharp sell-off in Thursday's session. Shares fell 12.6% to $8.74, down from a prior close of $10.00, marking one of the steepest single-day declines for the stock since its 2022 separation from GSK. The drop was triggered by a third-quarter trading update in which the company lowered its full-year revenue growth outlook, citing soft cold-and-flu consumption and a series of regional headwinds.
Guidance Cut Weighs on the Stock
The decisive catalyst behind the move was a downward revision to Haleon's full-year outlook. Management now expects organic revenue growth of around 2.5% for 2026, a meaningful step down from the 3% to 5% range it had guided to at its half-year results. Analysts had been forecasting roughly 3.2%, so the new target landed well below consensus expectations and triggered an earnings-driven sell-off as investors repriced the shares.
Weak Cold-and-Flu Season Hits Respiratory Health
Third-quarter organic revenue growth came in at 2.6%, below the company's own expectations. The shortfall was concentrated in the respiratory-health category, where organic revenue fell 2% as a subdued cough, cold, and flu season dampened consumption and led to lower orders in North America, Haleon's largest market. With price contributing 2.1% and volume/mix just 0.5%, the results underscored a reliance on pricing rather than underlying volume growth.
China and Brazil Add to the Pressure
Beyond the seasonal weakness, two regional issues compounded the outlook cut. In China, a change in raw-material classifications prompted the suspension of imports of over-the-counter Centrum multivitamins, weighing on the Vitamins, Minerals and Supplements category, which declined 0.5%. Separately, Haleon said it would accelerate planned changes to its Brazil go-to-market strategy into the fourth quarter, a move expected to reduce fourth-quarter net revenue by £15 million to £20 million.
Buyback Fails to Offset the Negative Read
Haleon sought to cushion the news by announcing a further £500 million share buyback, to be executed by Citigroup and completed by February 2027. Oral Health was a genuine bright spot, with organic revenue up 8.8% on strong Sensodyne performance. However, the buyback and the category strength were not enough to offset investor concern about weakening momentum across the wider portfolio, and shares remained firmly lower.
Market Context and Trading Activity
The sell-off in HLN ran against the grain of the broader tape, with the FTSE 100 trading higher on the day, underscoring that the decline was company-specific rather than a reflection of general market sentiment. Trading volume was elevated as investors reacted to the guidance revision. The move also aligned with pressure across the consumer-health sector, where rival Reckitt had earlier trimmed its own profit guidance amid manufacturing difficulties in its U.S. disinfectant business.
What Comes Next for HLN
Attention now turns to whether a stronger cold-and-flu season can restore momentum in the respiratory-health franchise and whether the company can resolve the China import disruption on Centrum. Investors will also monitor the execution of the Brazil transition and its impact on fourth-quarter revenue. Haleon reiterated its medium-term targets of 4% to 6% annual organic revenue growth and high-single-digit adjusted operating profit growth, but the near-term guidance reset leaves questions about the pace at which the business can return to that trajectory. Risks include further seasonal weakness, persistent consumer softness in Europe, and ongoing competitive pressures across the consumer-health sector.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that are performing strongly in the current market environment. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with strategies that vary by approach, timeframe, performance metrics, and traded symbols. Only the strongest performers under prevailing conditions are featured in this section. Explore Trending AI Robots to discover which automated strategies are leading the market today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HLN in -1.96% downward trend, sliding for three consecutive days on October 28, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where HLN declined for three days, in 117 of 220 cases, the price declined further within the following month. The odds of a continued downward trend are 53%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for HLN moved out of overbought territory on October 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 13 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 46%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 27 of 54 cases where HLN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 50%.
HLN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for HLN entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on HLN as a result. In 44 of 72 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.
The Moving Average Convergence Divergence (MACD) for HLN just turned positive on October 08, 2026. Looking at past instances where HLN's MACD turned positive, the stock continued to rise in 21 of 35 cases over the following month. The odds of a continued upward trend are 60%.
HLN moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for HLN crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 5 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 33%.
Following a +0.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where HLN advanced for three days, in 138 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 53%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. HLN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.685) is normal, around the industry mean (8.801). P/E Ratio (27.322) is within average values for comparable stocks, (-2.500). Projected Growth (PEG Ratio) (2.158) is also within normal values, averaging (2.152). Dividend Yield (0.026) settles around the average of (0.044) among similar stocks. P/S Ratio (2.739) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement